ReviewEpilepsia open2025
Status epilepticus: Updates on mechanisms and treatments.
Review in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genetic landscape of patients with atypical absence status epilepticus: A systematic review.Epilepsia open · 2026Pooled it
- Crinis Carbonisatus-Derived Carbon Dot Suspension Alleviates Temporal Lobe Epilepsy.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Status epilepticus (SE) consists of prolonged, self-sustaining seizures and is a common neurological emergency that causes respiratory compromise and neuronal injury. Without prompt treatment, the seizures can become resistant to benzodiazepines, leading to the progressive evolution of established, refractory, and super-refractory SE. Studies in experimental animals have found impaired GABAergic inhibition and potentiated glutamatergic neurotransmission in SE animals. These alterations increase the number of active neurons and expand the seizure network. Here, we first discuss the changes in GABA-A, NMDA, and AMPA receptor-mediated synaptic transmission during SE and elaborate on emerging studies showing the neuronal consumption of alternate energy sources to cope with increased energy demand. Then, we discuss the clinical studies that have tested the efficacy of various benzodiazepines and other anticonvulsant agents in treating SE in prehospital and in-hospital settings. Finally, we briefly summarize the ongoing clinical studies and the potential for other anticonvulsant agents to be tested for treating SE. PLAIN LANGUAGE SUMMARY: Most seizures are self-limiting, but some seizures change the brain such that a constant state of seizures, SE, is generated. These prolonged seizures can cause neuronal injury and increase the risk of death. We discuss the molecular mechanisms that sustain these seizures and the accompanying neuronal and network plasticity. We also review the current SE treatment and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.